Warning: We observe an increase of emails from fake travel portals like . "travelhosting.co.uk". We never send links to such portals so be vigilant!

Dec 8 – 10, 2020 Online only
Online event
Europe/Berlin timezone

Pharmaceutical Drug Carriers organized in Nano-Domains – Study and Design upon Neutron Scattering with contrast variation, SAXS and DLS

Dec 9, 2020, 2:30 PM
3h 30m
Online event

Online event

Poster DN: Life Science/ Biology Joint poster session of MLZ User Meeting and DN2020


Dr Thomas Nawroth (Gutenberg-University, Pharmaceutical Technology, Staudingerweg 5)


Specific target Nanoparticles for therapy of cancer and other diseases were assembled from lipids, polymers, and pharmaceutical drugs or mRNA. For cell targeting proteins were bound to the surface (corona). The structure in solution is analyzed by dynamic light scattering DLS combined with neutron small angle scattering SANS, SAXS, metal specific X-ray scattering ASAXS. Material sub-domains in the nanoscaled drug carriers (100 nm, polymer complexes, liposomes) were localized by contrast variation.
The nanoparticles, e.g. biodegradable polymer (PLGA, Carbohydrates), intestinal lipid-bile nanoparticles, lipid particles, proteins and optional bio-target domain are ampiphilic. Thus the internal particle structure forms sub-domains of different material and scattering power, enabling a localization by contrast. For several medical cases we construct and study pharma nanoparticles for parenteral and oral applications, which contain soluble or hydrophobic drugs, or nucleic acid drugs, e.g. mRNA. Cell or tumor recognition and uptake of the drug carriers can obtained by a surface protein, ligand head.
mRNA nano-complexes for immune-vaccination and cancer therapy work by cellular synthesis of the corresponding protein (not the antigen, but the genetic information for it is supplied). Oral nano-drug application is tested with a simulator device of the gastro-intestinal tract with SANS-DLS observation of drug nanoparticles and intermediates.

Primary author

Dr Thomas Nawroth (Gutenberg-University, Pharmaceutical Technology, Staudingerweg 5)


Dr Christian Siewert (Universität Mainz) Dr Antje Ziller (Universität Mainz) Mr Lukas Uebbing (Universität Mainz) Mr Michael Patrick Klak (Universität Mainz) Mrs Vera Cornet (University Mainz) Dr Jozef Al-Gousous (University Mainz) Prof. Urgur Sahin (University Medicine Mainz, BioNTech) Dr Heinrich Haas (BioNTech SE and University Medicine, Mainz) Mrs Sarah Nogueira (BioNTech SE, University Mainz) Dr Raphael Johnson (Nkrumah University) Dr Dimitri Svergun (EMBL c.o. DESY) Dr Martin Schroer (EMBL c.o. DESY P12) Guenter Goerigk (Helmholtz-Zentrum-Berlin) Ralf Schweins (Institut Laue - Langevin) Aurel Radulescu (Forschungszentrum Jülich GmbH, Jülich Centre for Neutron Science at MLZ) Tobias Schrader Prof. Peter Langguth (University Mainz)

Presentation materials